Wake Forest School of Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC.
Department of Otolaryngology-Head and Neck Surgery, University of California at San Francisco, San Francisco, CA.
Semin Radiat Oncol. 2018 Jan;28(1):2-11. doi: 10.1016/j.semradonc.2017.08.005.
Large-scale sequencing studies of head and neck squamous cell carcinoma (HNSCC) have elucidated the genetic changes that characterize HNSCC. These findings have supported the development of therapeutic strategies that target key components of aberrant signaling pathways and immune dysregulation. Cumulative evidence suggests that these agents in combination with radiotherapy may have synergistic effects. This review highlights the predictive biomarkers that have been identified from HNSCC genomic studies and implications on the development of molecular-targeting agents that may effectively treat patients with HNSCC, especially when used in combination with radiation.
大规模的头颈部鳞状细胞癌（HNSCC）测序研究阐明了HNSCC 的遗传变化。这些发现支持了开发治疗策略的发展，这些策略针对异常信号通路和免疫失调的关键成分。累积的证据表明，这些药物与放疗联合使用可能具有协同作用。本综述强调了从 HNSCC 基因组研究中确定的预测生物标志物及其对分子靶向药物开发的影响，这些药物可能对头颈部鳞状细胞癌患者有效治疗，尤其是与放疗联合使用时。
